(Health Korea News / Soon-ho Lee) On the 15th, the three largest shareholders of Hanmi Science (Hanyang Precision Chairman Shin Dong-guk, Hanmi Pharmaceutical Group Chairman Song Young-sook, and Vice Chairman Lim Joo-hyun) filed a complaint against his mother and others through the founder’s eldest son, Director Lim Jong-yoon, using the private company’s representative (Han Seong-jun). Regarding one case, “Brothers blinded by management rights were afraid and anxious about the special resolution to change the Articles of Incorporation, so they made accusations and accusations against humanity. “It’s being overused,” he said. (See related article below)
The three-member alliance said in a statement on the 18th, “Since the foundation was established in accordance with the wishes of founder and Chairman Lim Seong-gi, it has been operated through donations from Korea and the United States for the past 20 years without any legal problems,” adding, “Even Director Lim Jong-yoon became the CEO of Hanmi Science.” He explained, “Even during the 10 years I was in office, donations to the foundation were made without a resolution from the board of directors.”
He continued, “Minority shareholders are turning their backs on the extreme brotherly management shown over the past seven months, and as the possibility of passing the special resolution proposed by the three-party alliance has emerged, anxious brothers are making excessive accusations and accusations that violate humanity.” He pointed out, “The brothers should know that many shareholders are holding their tongues at the fact that they do not hesitate to report their own mothers using any means possible.”
In fact, Hanmi Science donated approximately 7.6 billion won during the time of CEO Lim Jong-yoon, and current CEO Lim Jong-hoon donated 900 million won to the foundation without board approval, according to the three-person alliance.
According to the three-person alliance, Hanmi Pharmaceutical donated 11.7 billion won during the time of former CEO A, the predecessor of Hanmi Pharmaceutical CEO Park Jae-hyun. Since then, 5.2 billion won, which is about half of the 11.9 billion won that CEO Jae-hyun Park decided to donate, was donated during the time of former CEO A, and criticism has been raised that the lawsuit was intentionally inflated to pressure CEO A.
Currently, former CEO A has signed a strategic business agreement with the company he manages and DxVx, President Lim Jong-yoon’s personal company. However, due to Director Lim Jong-yoon’s endless accusations, former CEO A is now in a situation where he must be investigated. .
The three-member alliance said, “In particular, the second son, CEO Lim Jong-hoon, sent an official letter to the foundation to the effect that ‘donations will be withheld until a letter of confirmation is written’ without any mention of the ‘board resolution’ until recently, and the foundation did not provide a letter of confirmation. “I understand that the transaction between voting rights and donations has been completed at the moment and no action can be taken,” he said. “It is clear that as an independent public interest corporation, it is up to the board members to make their own decisions. He said, “I cannot help but wonder whether the executives really have reason, given that they are exerting serious pressure that goes beyond external pressure.”
An official from the three-person union said, “Taking these circumstances into consideration, directors Lim Jong-yoon (eldest son) and Lim Jong-hoon (second son) can be accused of false accusation, but the subject who can be accused is the mother, Chairman Song Young-sook, and it would be against humanity for a parent to sue his child. “I am very concerned about what could happen, so I am restraining myself as much as possible with a mother’s heart,” he said. “It is very sad that two sons who know better than anyone else the contribution of Chairman Song Young-sook, who devoted himself to the Korea-U.S. Public Foundation, are doing this to their mother.” “I feel devastated,” he said.
In a recent phone call with Health Korea News, a Hanmi Pharmaceutical official also said, “Director Lim Jong-yoon and CEO Lim Jong-hoon, who are executives of Hanmi Science, are the biological sons of the late Chairman Lim Seong-gi and Chairman Song Young-sook,” adding, “The stocks (property) of the two sons are owned by both parents anyway.” He reacted angrily, saying, “It was passed down to me, so how can the son report his mother?”
This official, who has served Chairman Lim Seong-ki closely at Hanmi Pharmaceuticals for a long time, said, “Chairman Lim Seong-ki suffered a lot because his two sons got into a lot of trouble when he was alive,” adding, “That is why Chairman Lim even had a plan for the succession of Hanmi Pharmaceuticals. You had a lot to worry about. He also said, “I trusted my daughter, Vice Chairman Lim Joo-hyun, more than my two sons.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
